



Potential Molecular Targets and Therapeutics in Triple-Negative Breast Cancer

Guest Editors:

Dr. Maryam Nakhjavani

School of Medicine, Faculty of
Health, Deakin University, 75
Pigdons Road, Waurin Ponds, VIC
3216, Australia

Dr. Amanda R. Townsend

Medical Oncology Unit, The
Queen Elizabeth Hospital,
Woodville South, SA 5011,
Australia

Deadline for manuscript
submissions:

closed (29 October 2021)

Message from the Guest Editors

Triple-negative breast cancer (TNBC) is a subtype breast cancer that lacks any targeted therapy, and despite current improvements in the treatment of breast cancer patients, fewer drugs have been approved and are available to these patients, especially those with metastatic TNBC.

This Special Issue aims to integrate recent improvements in finding molecular targets and innovative approaches in the treatment of metastatic TNBC with an effort to expand the knowledge on a wide range of topics in this field. I would like to sincerely invite you to contribute on this Special Issue with your research articles and reviews, which include but are not limited to the following topics: molecular targets, signalling pathways, miRs, gene expression and multigene predictors, role of epigenetics, stem cells, single or combination treatments, targeted treatments and novel targeted formulations, animal models, and clinical outcomes.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com